uniQure (NASDAQ:QURE) Shares Gap Down - Here's Why

Shares of uniQure (NASDAQ:QURE - Get Free Report) gapped down before the market opened on Monday . The stock had previously closed at $12.47, but opened at $11.34. uniQure shares last traded at $10.38, with a volume of 548,019 shares changing hands.

Wall Street Analyst Weigh In

Several analysts have weighed in on the stock. Cantor Fitzgerald boosted their price target on shares of uniQure from $28.00 to $58.00 and gave the stock an "overweight" rating in a research note on Tuesday, December 10th. Wells Fargo & Company lowered their target price on uniQure from $35.00 to $30.00 and set an "equal weight" rating for the company in a research note on Friday, February 28th. Stifel Nicolaus raised their price target on uniQure from $12.00 to $32.00 and gave the stock a "buy" rating in a research report on Monday, December 16th. Mizuho lifted their price target on uniQure from $7.00 to $20.00 and gave the stock a "neutral" rating in a research note on Thursday, December 19th. Finally, Royal Bank of Canada reissued an "outperform" rating and set a $24.00 price objective on shares of uniQure in a research note on Tuesday, January 21st. One research analyst has rated the stock with a sell rating, three have issued a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, uniQure currently has a consensus rating of "Moderate Buy" and an average price target of $38.80.

uniQure Stock Down 8.1 %

The company has a debt-to-equity ratio of 0.92, a current ratio of 6.51 and a quick ratio of 6.51. The stock has a market capitalization of $484.53 million, a PE ratio of -1.81 and a beta of 0.37. The company has a 50 day moving average price of $13.38 and a 200-day moving average price of $10.88.

Insider Activity

In other news, CFO Christian Klemt sold 14,341 shares of uniQure stock in a transaction that occurred on Tuesday, February 25th. The shares were sold at an average price of $10.70, for a total transaction of $153,448.70. Following the completion of the transaction, the chief financial officer now directly owns 152,372 shares in the company, valued at approximately $1,630,380.40. This trade represents a 8.60 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Matthew C. Kapusta sold 26,727 shares of the firm's stock in a transaction that occurred on Tuesday, February 25th. The shares were sold at an average price of $10.70, for a total value of $285,978.90. Following the transaction, the chief executive officer now directly owns 571,188 shares of the company's stock, valued at approximately $6,111,711.60. This trade represents a 4.47 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 90,830 shares of company stock valued at $961,401. Corporate insiders own 4.74% of the company's stock.

Hedge Funds Weigh In On uniQure

Institutional investors and hedge funds have recently modified their holdings of the stock. Avoro Capital Advisors LLC bought a new stake in uniQure during the 4th quarter valued at about $38,410,000. Franklin Resources Inc. purchased a new position in uniQure in the 3rd quarter worth approximately $7,360,000. RTW Investments LP lifted its position in uniQure by 8,936.3% in the 4th quarter. RTW Investments LP now owns 903,625 shares of the biotechnology company's stock valued at $15,958,000 after acquiring an additional 893,625 shares in the last quarter. Point72 Asset Management L.P. boosted its stake in uniQure by 81.3% during the 4th quarter. Point72 Asset Management L.P. now owns 1,771,352 shares of the biotechnology company's stock valued at $31,282,000 after purchasing an additional 794,459 shares during the last quarter. Finally, Boxer Capital Management LLC bought a new stake in shares of uniQure in the 4th quarter worth $13,245,000. 78.83% of the stock is currently owned by institutional investors.

About uniQure

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.